These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18553043)

  • 1. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat.
    Mikosch P; Reed M; Baker R; Holloway B; Berger L; Mehta AB; Hughes DA
    Calcif Tissue Int; 2008 Jul; 83(1):43-54. PubMed ID: 18553043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM; Elstein D; Hrebícek M; Zimran A
    Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM; Barnett NL; Kolodny EH
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaucher disease: unmet treatment needs.
    Mehta A
    Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase.
    Parisi MS; Mastaglia SR; Bagur A; Goldstein G; Zeni SN; Oliveri B
    Eur J Med Res; 2008 Jan; 13(1):31-8. PubMed ID: 18226995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.
    Weinreb NJ; Barranger JA; Charrow J; Grabowski GA; Mankin HJ; Mistry P
    Am J Hematol; 2005 Nov; 80(3):223-9. PubMed ID: 16247743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C; Swiader L; Serratrice J
    J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
    Capablo JL; Franco R; de Cabezón AS; Alfonso P; Pocovi M; Giraldo P
    Epilepsia; 2007 Jul; 48(7):1406-8. PubMed ID: 17433057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
    Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
    [No Abstract]   [Full Text] [Related]  

  • 10. Goal-oriented therapy with miglustat in Gaucher disease.
    Pastores GM; Giraldo P; Chérin P; Mehta A
    Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
    Moyses C
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gaucher disease and its treatment options.
    Bennett LL; Mohan D
    Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
    J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
    Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
    Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate reduction therapy.
    Platt FM; Jeyakumar M
    Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy.
    Puzo J; Alfonso P; Irun P; Gervas J; Pocovi M; Giraldo P
    Atherosclerosis; 2010 Apr; 209(2):515-9. PubMed ID: 19959168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
    Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
    Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy.
    Ciana G; Addobbati R; Tamaro G; Leopaldi A; Nevyjel M; Ronfani L; Vidoni L; Pittis MG; Bembi B
    J Inherit Metab Dis; 2005; 28(5):723-32. PubMed ID: 16151904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
    Javier RM; Hachulla E
    Presse Med; 2007 Dec; 36(12 Pt 3):1971-84. PubMed ID: 17498916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.